Vaxonco, Inc.'s EP1300 Epitope-Based DNA Vaccine for Malaria Delivered by Ichor Medical Systems, Inc. TriGrid(TM) Electoporation Enters Phase I Trial
9/23/2010 11:55:13 AM
SEOUL, South Korea & SAN DIEGO--(BUSINESS WIRE)--Vaxonco Inc., a Korean company specializing in peptide-based vaccines and Ichor Medical Systems (Ichor), whose advanced TriGrid™ Delivery System (TriGrid™) is being tested worldwide for its ability to enhance delivery of DNA drugs and vaccines, announced today the initiation of a Phase I clinical trial to evaluate a novel DNA-based polyepitope vaccine against malaria. The study is supported by the United States National Institutes of Health and Vaxonco, Inc.’s subsidiary Epimmune, Inc and EP1300 will be delivered using Ichor’s TriGrid™. The study will be conducted as a randomized, prospective, placebo-controlled, dose-escalating trial at the Emory Vaccine and Treatment Evaluation Unit in Atlanta, Georgia, and will be supported by the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health.
comments powered by